1-16 of 16
N O'Donovan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract P5-03-02: Pre-clinical investigation of PP2A inhibitor LB-100 in overcoming and preventing lapatinib resistance in HER2-positive breast cancer

N Conlon, M McDermott, B Browne, S Roche, F O'Neill, J Meiller, A Browne, A Eustace, DM Collins, N O'Donovan, J Crown
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): P5-03-02.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-P5-03-02
Published: 15 February 2019
View article
Journal Articles

Abstract P4-03-15: Targeting Src kinase blocks development of afatinib resistance in HER2-positive breast cancer

N Conlon, A Canonici, C Morgan, M Cremona, BT Hennessey, A Eustace, N O'Brien, D Slamon, J Crown, N O'Donovan
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): P4-03-15.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-P4-03-15
Published: 15 February 2018
View article
Journal Articles

Abstract P5-11-03: Tumor CXCL16/CXCR6 expression and soluble CXCL16 in HER2+ breast cancer (BC)

DM Collins, SF Madden, AJ Eustace, S Toomey, EW Kay, J Fay, N O'Donovan, WM Gallagher, B Hennessy, J Crown
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): P5-11-03.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-P5-11-03
Published: 15 February 2018
View article
Journal Articles

Abstract P4-21-27: Plasma chemokine profile of HER2+ breast cancer (BC) patients treated with docetaxel (D) and carboplatin (C) in combination with trastuzumab (T) and/or lapatinib (L) in the neo-adjuvant setting

DM Collins, SF Madden, N Gaynor, WM Gallagher, N O'Donovan, J Crown
Journal: Cancer Research
Cancer Res (2017) 77 (4_Supplement): P4-21-27.
DOI: https://doi.org/10.1158/1538-7445.SABCS16-P4-21-27
Published: 15 February 2017
View article
Journal Articles

Abstract P1-05-18: Genomic copy number alterations (CNA) associated with pCR in HER2-positive (HER2+) early-stage breast cancer (BrCa) patients receiving neoadjuvant trastuzumab (T)

N Walsh, G Gullo, A Maguire, N O'Donovan, C Quinn, J Crown
Journal: Cancer Research
Cancer Res (2017) 77 (4_Supplement): P1-05-18.
DOI: https://doi.org/10.1158/1538-7445.SABCS16-P1-05-18
Published: 15 February 2017
View article
Journal Articles

Abstract P4-12-01: Long term follow up of patients (pts) with HER2positive (H+) early stage breast cancer (ESBC) treated with trastuzumab (T)

R Bose, D Zanoni, G Gullo, D Fennelly, J Walshe, J Ballot, A Defrein, N O'Donovan, E Mc Dermott, D Evoy, N Silva, J Crown
Journal: Cancer Research
Cancer Res (2016) 76 (4_Supplement): P4-12-01.
DOI: https://doi.org/10.1158/1538-7445.SABCS15-P4-12-01
Published: 15 February 2016
View article
Journal Articles

Abstract P4-12-25: Randomized phase II study of pre-operative docetaxel, carboplatin with trastuzumab (TCH) and/or/lapatinib (L) in HER-2 positive (H+) breast cancer patients (BC pts). ICORG 10-05

J Crown, L Coate, M Keane, J Kennedy, S O'Reilly, C Kelly, M O'Connor, M Martin, K Duffy, C Murphy, J Walshe, T O'Shea, B Moulton, K Egan, N O'Donovan, G Gullo, K Geraghty, B Hennessy
Journal: Cancer Research
Cancer Res (2013) 73 (24_Supplement): P4-12-25.
DOI: https://doi.org/10.1158/0008-5472.SABCS13-P4-12-25
Published: 15 December 2013
View article
Journal Articles

Abstract P3-04-12: BreastMark: An integrated approach to mining publically available Transcriptomic Datasets relating to Breast Cancer Outcome

S Madden, P Gaule, C Clarke, ST Aherne, N O'Donovan, M Clynes, J Crown, WM Gallagher
Journal: Cancer Research
Cancer Res (2012) 72 (24_Supplement): P3-04-12.
DOI: https://doi.org/10.1158/0008-5472.SABCS12-P3-04-12
Published: 15 December 2012
View article
Journal Articles

Abstract OT1-1-06: A phase III randomized study of Paclitaxel and Trastuzumab versus Paclitaxel, Trastuzumab and Lapatinib in first line treatment of HER2 positive metastatic breast cancer.

JP Crown, B Moulton, N O'Donovan
Journal: Cancer Research
Cancer Res (2012) 72 (24_Supplement): OT1-1-06.
DOI: https://doi.org/10.1158/0008-5472.SABCS12-OT1-1-06
Published: 15 December 2012
View article
Journal Articles

P1-12-06: The Role of MAPK and PI3K/AKT/mTOR Signaling in Innate Lapatinib Resistance.

M McDermott, N O'Brien, K McDonald, J Crown, N O'Donovan, D Slamon
Journal: Cancer Research
Cancer Res (2011) 71 (24_Supplement): P1-12-06.
DOI: https://doi.org/10.1158/0008-5472.SABCS11-P1-12-06
Published: 15 December 2011
View article
Journal Articles

P3-17-03: ADAM17: A Novel Therapeutic Target for Treatment of Triple Negative Breast Cancer.

PM McGowan, M Mullooly, S Sukor, S Madden, E McDermott, A Pierce, J Crown, N O'Donovan, MJ Duffy
Journal: Cancer Research
Cancer Res (2011) 71 (24_Supplement): P3-17-03.
DOI: https://doi.org/10.1158/0008-5472.SABCS11-P3-17-03
Published: 15 December 2011
View article
Journal Articles

P5-06-09: Acquired Sensitivity to TRAIL Mediated Apoptosis in Lapatinib Resistant SKBR3 Cells.

AJ Eustace, BC Browne, M McDermott, C Gallagher, W Watson, J Crown, N O'Donovan
Journal: Cancer Research
Cancer Res (2011) 71 (24_Supplement): P5-06-09.
DOI: https://doi.org/10.1158/0008-5472.SABCS11-P5-06-09
Published: 15 December 2011
View article
Journal Articles

Abstract P4-01-06: The Role of the PI3K/AKT, RAS/MAPK and Novel Signaling Pathways in Resistance to HER2-Targeted Therapy

NA O'Brien, K Wilcox, M McDermott, J Crown, N O'Donovan, DJ. Slamon
Journal: Cancer Research
Cancer Res (2010) 70 (24_Supplement): P4-01-06.
DOI: https://doi.org/10.1158/0008-5472.SABCS10-P4-01-06
Published: 15 December 2010
View article
Journal Articles

Constitutive Activation of Src Kinase as a Mechanism of Acquired Resistance to Dasatinib in Triple Negative Breast Cancer.

B. Corkery, B. Corkery, J. Crown, J. Crown, S. Roche, R. O'Connor, D. Tryfanopoulos, D. Tryfanopoulos, M. Clynes, N. O'Donovan
Journal: Cancer Research
Cancer Res (2009) 69 (24_Supplement): 5066.
DOI: https://doi.org/10.1158/0008-5472.SABCS-09-5066
Published: 15 December 2009
View article
Journal Articles

Combining HSP90 Inhibition with Standard Therapies for HER2 Positive Breast Cancer.

Z. Qadir, Z. Qadir, J. Crown, J. Crown, M. Jensen, M. Clynes, D. Slamon, N. O'Donovan
Journal: Cancer Research
Cancer Res (2009) 69 (24_Supplement): 5055.
DOI: https://doi.org/10.1158/0008-5472.SABCS-09-5055
Published: 15 December 2009
View article
Journal Articles

The role of receptor tyrosine kinase and activated PI3K signaling in response/resistance to HER-2 targeted therapy.

NA O'Brien, BC Browne, L Chow, C Ginther, B Bensadigh, J Arboleda, MJ Duffy, J Crown, N O'Donovan, DJ Slamon
Journal: Cancer Research
Cancer Res (2009) 69 (2_Supplement): 2013.
DOI: https://doi.org/10.1158/0008-5472.SABCS-2013
Published: 15 January 2009
View article